EpiCept completes enrollment in European trial of LidoPAIN for post-op pain relief

By Elaine Rigoli

Tampa, Fla., Aug. 17 - EpiCept Corp. has completed patient enrollment in its multi-center, randomized, double-blind, placebo-controlled phase 3 pivotal trial in Europe for the company's LidoPAIN SP product.

LidoPAIN SP is a sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound while also providing a sterile protective covering for the wound.

Currently, there is no marketed product similar to LidoPAIN SP, the company said in a news release.

"We believe this phase 3 trial is designed to adequately support a LidoPAIN SP marketing application in Europe. In addition, as part of our strategic alliance with Adolor, clinical trials for this product candidate in North America are progressing. We anticipate being able to share the results of the phase 3 trial later this month," president and chief executive officer Jack Talley said in the release.

EpiCept is an emerging specialty pharmaceutical company located in Englewood Cliffs, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.